Christian Kampf 康可安 💊

📝 Big Pharma’s focus on profit is behind medicine shortages, superbug threat. We cannot navigate the global health crises we are facing under our current profit-oriented medicine development and manufacturing system. What happens when we run out of medicines? Medical authorities around the world are pondering this question as they struggle with shortages of a range of essential medicines amid a global drug supply crisis. Separately, England’s former chief medical officer Sally Davies, warns us of the growing threat posed by drug-resistant superbugs. The antimicrobial resistance crisis could make the COVID-19 pandemic “look minor”, Davies claims, if not met with urgent action, including the development of new antibiotics. At first glance, these two crises seem to have little in common other than the serious threat they pose to human life. But they are, in fact, born out of a single problem: Big Pharma’s prioritisation of profit, which disincentivises it from both keeping essential medicines accessible and developing new medicines we desperately need. The growing threat from antimicrobial resistance is also a direct consequence of Big Pharma’s focus on profit – the only difference is that at the root of this crisis are choices made regarding research and development, rather than manufacturing. “Superbugs” – bacteria, viruses, parasites or fungi that have developed resistance to usual treatments – have long been a concern for the medical community. Experts agree that the development of new antibiotics will be crucial to tackling the problem. Yet, shockingly, not a single new class of antibiotic has been invented since the 1980s. And this is a choice made by Big Pharma. Pharmaceutical companies have long turned their noses up at producing new antibiotics because they do not believe such an endeavour would be sufficiently profitable. Rather than potentially lifesaving antibiotics, they are focusing their research and development efforts on so-called “Me too” drugs, which are developed through minor modifications to existing drugs and rarely represent a meaningful therapeutic advance, but promise continued profitability. With vital drugs in short supply and drug-resistant pathogens a growing danger, it may seem perverse that pharmaceutical companies are placing their bottom line above the health of everyday people. But at the end of the day, these companies are beholden to their shareholders, not global health. Our current model of medicine production which puts shareholder returns above all else means patients are beholden to these dynamics. In any case, humanity cannot pay its way out of these crises, because not every country has the means to feed corporate greed. What happens to patients in countries that cannot afford the ever-increasing price tag? The horrific “vaccine apartheid” we witnessed at the height of the COVID-19 pandemic is perhaps the best demonstration of how such a strategy plays out on a global stage. [Al Jazeera Media]. #OPINION✏️

3

𝐒𝐰𝐢𝐬𝐬 𝐯𝐨𝐭𝐞𝐫𝐬 𝐫𝐞𝐣𝐞𝐜𝐭 𝐥𝐢𝐦𝐢𝐭𝐬 𝐨𝐧 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐬𝐩𝐞𝐧𝐝𝐢𝐧𝐠 Swiss Voters Reject Healthcare Reforms in June 9 Referendum. On June 9, Swiss voters decided on two significant healthcare initiatives aimed at addressing rising healthcare costs. The first initiative, proposed by the Social Democratic Party, sought to cap health insurance premiums at 10% of household income, with the government subsidizing any excess costs. This proposal aimed to alleviate the financial burden on households struggling to pay their health insurance bills. Despite initial support, the initiative faced skepticism regarding its financial sustainability, with concerns about potential tax increases and additional burdens on families. Ultimately, only 44% of voters supported the initiative, leading to its rejection. The second initiative, proposed by the Centre Party, introduced a "cost brake" mechanism, which mandated government intervention if healthcare costs rose more than 20% above wage increases. This proposal intended to compel all stakeholders in the healthcare sector to implement cost-saving measures. However, it failed to garner widespread support, with critics arguing that it did not account for factors such as demographic changes and medical advancements. The initiative also struggled to gain traction outside the Centre Party, and 63% of voters ultimately opposed it. These results reflect the Swiss electorate's cautious approach to implementing extensive healthcare reforms, demonstrating significant concerns about the financial implications and feasibility of such measures. Source: swissinfo.ch, 10.6.24 #healthcare #insurance #switzerland

5

3 Kommentare

🚀 Hyntelo and Daiichi Sankyo drive innovation in data management. Daiichi Sankyo needed to improve its sales data management and internal activities to create user-friendly reports that meet the needs of various departments. Together we decided to implement a smart data management solution to streamline reporting processes. ⚠️ Want to know more? Read our case study 👉 https://lnkd.in/dDwSWwPH #Hyntelo #AI #ArtificialIntelligence

27

2 Kommentare

👩‍⚕️Every pharmacist knows, how important it is to follow hygiene standards when preparing medications, especially sterile ones for intravenous or eye application. 🧑‍⚕️Our knowledge and respect for patients guide us in this work. 🎥 Watch our new video to learn more. The European Statements of Hospital Pharmacy, section 3: production and compounding Národný ústav srdcových a cievnych chorôb, a.s. The European Association of Hospital Pharmacists (EAHP) #hospitalpharmacy #drugcompounding #medicine #healthcare #hygiene

99

5 Kommentare

Patients can’t benefit from what they don’t understand. Don’t let poor communication keep your solution from reaching the right patients. 🩺 Rheumatology innovators Patiently’s engagement solution ensures your innovative treatment connects with the patients who need it most. 💡 Drop the name of your solution and the disease you’re solving in the comments, and let’s make sure the right patients find your breakthrough. 🚀 #Rheumatology #HealthTech #PatientEngagement #RightPatientRightCare #InnovativeHealthcare #MedTech #DigitalHealth #HealthcareInnovation #Patiently

1

#Eczema affects 2-10% of the adult population worldwide and remains a huge socioeconomic and QoL burden. During the COVID-19 pandemic many on-site consultations have been replaced by video calls and transmission of digital camera #images. In order to reduce the health care burden, but also enable patients to self-monitor the underline disease, #AI solutions have been developed for eczema area detection and prediction of its severity. The current literature search was looking relevant papers that have been published in English language as of 2014 and onwards. The search captured 25 articles that 12 of them describing algorithms used in the prediction of eczema #severity, while the remaining 13 in the detection of the affected #area. The article is discussing the appraisal of identified studies, the limitations of AI published algorithms and concludes with authors suggestions on potential improvements. In the rest of the post , I will be highlighting the main limitations, which are consistent across TAs: - Samples are not representative of the entire population, leading to bias. Particularly age and ethnicity are predictors of eczema severity. - Training set should be composed by huge number of images, which is not always the case due to data privacy and lack of a centralized repository. - Eczema areas characterized by variant sizes across the entire population, that might contribute to error-prone eczema area labels. - Inaccessible Hospital data due to ethical restrictions, make difficult to compare results or even reproduce them. - Standardized images for whole body assessment is an additional hurdle, compared to protocolise images targeting localized areas like the hands. In my opinion there is still a lot of work to be done in #Dermatology and we need many more consortia until we develop AI-solutions that target patients and HC system benefits. However, this is not the main message I want to convey. This morning, while I was educating myself on AI, I met a Golden Retriever Service dog, wearing a uniform stating “Best friend”. Talking to the owner, he mentioned that these clever dogs are used in therapies of autistic children. I was touched hearing that children who have not spoken for years, have been communicating to the dog, their “Best Friend”. It was such a warm feeling realizing that although AI is on our way, certain things can never been overtaken by a machine algorithm! Disclaimer: The opinions shared are solely my own and do not express the views or opinions of any of my employers.

17

💡 How Artificial Intelligence Opens New Horizons in Cancer Treatment – and What We Don’t Even Know We Don’t Know 💡 Philosopher Martin Heidegger emphasized the importance of recognizing different levels of knowledge and ignorance. According to him, there are three types of knowledge: what we know, what we know we don’t know, and what we don’t even know we don’t know. In today’s AI era, these insights feel more relevant than ever, especially as AI breaks new ground in fighting diseases like glioblastoma, one of the most aggressive forms of brain cancer. 🔬 Artificial Intelligence is revolutionizing glioblastoma treatment. Researchers are now using AI to reprogram cancer cells into immune cells capable of targeting the tumor. Additionally, AI assists in diagnosing and predicting outcomes by analyzing imaging and molecular data, identifying tumor subtypes, and detecting genetic mutations. These insights are helping to personalize therapies and predict patient survival, giving doctors powerful new tools. Could it be that AI itself acts as an “illuminator of the unknown,” showing us questions and insights we didn’t even know to ask? This technology doesn’t just provide answers – it reveals new questions, expands our knowledge, and opens doors to possibilities we hadn’t seen before. AI reminds us that to truly advance, we must dare to explore not only what we know we don’t know, but also what lies beyond our current understanding. #ArtificialIntelligence #AI #HealthcareInnovation #CancerResearch #Glioblastoma #Heidegger #FutureOfMedicine #Knowledge #AIForGood

1

Curious about how Origify can transform pharmaceutical authentication 🏥? Explore our approach in the latest pharmind article by ECV - Editio Cantor Verlag GmbH titled "Digitaler Fingerabdruck: Authentifizierung für Medizin- und Pharmaprodukte“. Discover more by following this link 🔗: https://lnkd.in/ejdzrWkU, and don't hesitate to share your thoughts in the comments section below 📝.   #Bosch #Origify #ProductAuthentication #PharmaceuticalAuthentication #DigitalFingerprint #Pharmind  

22

4 Kommentare

Traditional marketing is challenged. Everything traditional is challenged. If you want to be the best, and to stand out your need to have #growthmindset and you need to have a team thinking outside of the box. This means we need to cherish different skills, especially when you are a #startup I recently listened to this 20VC podcast which was incredibly useful to understand what it means to have a growth leader and a team, if you are one or not. In the universe of #AI it gets even more essential to have a clear strategy for growth. The link is 👇 #startuplife #marketing #designthinking

15

1 Kommentar

I welcome you all my dears Do you know? = Innovation-focused businesses are 20% to 80% more profitable =17% of revenues of the world's most innovative companies comes from new products and services =43% of companies have acquired a startup to drive innovation =High-growth companies are 50% more likely to prioritize innovation

3

For many years, Stratenym has been supporting clients with market access strategy in a way that closely follows the key suggestions outlined in Mario Draghi's report. We have found that aligning with EU regulations and optimising evidence strategies for our clients results in positive recommendations as payers increasingly adopt a holistic view of the value chain, following the trend highlighted by Mario Draghi. #MarketAccess

4

Think Sunshine Is Enough? Here’s Why You May Still Need Vitamin D Support! Living in a sunny country doesn’t always guarantee you’re getting enough vitamin D. Darker skin tones and factors like spending more time indoors mean many people still face vitamin D deficiencies. 🔬 Here’s what you might not know: Darker skin tones contain more melanin, which acts as a natural sunblock, limiting the skin’s ability to produce vitamin D from sunlight. This means individuals with darker skin need 3 to 5 times more sun exposure than those with lighter skin to produce the same amount of vitamin D. Even if you live in a sunny region, your body may still not produce enough vitamin D, especially if you spend most of your time indoors or avoid direct sunlight. Without enough vitamin D: ·        Children may experience growth problems, weakened bones, and frequent infections. ·        Adults can suffer from fatigue, muscle pain, and an increased risk of bone fractures. 💡 The best way to ensure healthy vitamin D levels is to check regularly and consider supplementation where needed. 👉 Have you ever wondered if you’re getting enough vitamin D, even if you live in a sunny region? Let’s talk in the comments below. #VitaminD #SunlightAndVitaminD #DarkerSkinVitaminD #VitaminDSupport #KSMCLaboratories

12

1 Kommentar

HealthTech is revolutionizing patient care, but are we doing enough? 🚀 Tech and healthcare now unite, offering wonders from global telemedicine to real-time vitals tracking. AI integration shrinks error margins, revamping treatments and preventive care. But is it accessible to all? The HealthTech scene is ripe for entrepreneurs and investors. There's a wealth of opportunity for innovations with global impact and attractive ROI. Let's not forget the goal: democratizing advancements. How can we use our resources, insights, and networks to close the healthcare accessibility gap? Let's ignite the next HealthTech revolution. Innovate for impact! 💡🌍

4

3 Kommentare

😮 28% of Executives believe their boards have the right combination of skills and experience. 😮 92% think at least one board member should be replaced. Some shocking numbers. BSP through our partner network aim to ensure the right skills/expertise and incentives are a key part of board composition.

28

2 Kommentare